Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney disease ZHUBEI CITY, Taiwan and RALEIGH, N.C., June 5, 2026 /PRNewswire/ -- Bio Preventive Medicine Corp. and Precision Diabetes, Inc. today announced presentation of a...
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney disease ZHUBEI CITY, Taiwan and RALEIGH, N.C., June 5, 2026 /PRNewswire/ -- Bio Preventive Medicine Corp. and Precision Diabetes, Inc. today announced presentation of a...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.